The Quiet Shift in Private Capital Allocation
Royalty-based lending funds have spent years as an obscure corner of private credit, favored mainly by mining companies and early-stage pharmaceutical firms looking to avoid diluting equity. Now, family offices are moving into this space with noticeable intent – and doing it without much fanfare.
Why Royalty Structures Appeal to Long-Duration Capital
The basic mechanic is straightforward: a fund provides upfront capital to a company in exchange for a percentage of future revenue or gross profit, rather than fixed interest payments tied to a debt schedule. This creates a return profile that floats with the borrower’s commercial performance rather than sitting inside the rigid amortization structures of traditional private credit. For a family office managing wealth across generations, that difference matters more than it might for a pension fund chasing quarterly benchmarks.
Family offices have long preferred assets that generate predictable, recurring cash flows without requiring constant reinvestment decisions. Royalty streams fit that preference almost perfectly. Once a royalty agreement is in place, the fund collects its percentage as long as the underlying company generates revenue – which, in sectors like natural resources, music rights, or consumer brands, can stretch for decades. The compounding effect on that kind of duration is significant, particularly when the royalty rate was set during a period of stress when asset owners accepted unfavorable terms to access liquidity.
The broader appeal also comes from where royalty funds sit in a company’s capital structure. Unlike secured debt, royalty agreements are not typically subject to the same enforcement mechanisms during a default scenario, but they also avoid the subordination risks that plague mezzanine and junior debt. The royalty holder is essentially a silent revenue participant, not a creditor in the traditional sense. That distinction creates a cleaner legal position in restructuring scenarios and avoids the adversarial dynamic that can erode recoveries in conventional lending.
Family offices that have already been building positions in distressed commercial mortgage-backed securities are applying a similar logic here: find assets where the complexity of the structure has suppressed institutional demand, price that complexity appropriately, and hold long enough to capture the full yield. Royalty funds offer that same arbitrage, with the added benefit that the complexity is mostly front-loaded in the underwriting rather than distributed across the holding period.
Where the Capital Is Actually Going
The sectors attracting the most royalty-based capital from family offices right now cluster around three areas: natural resources, specifically royalties on producing mines and oil wells; life sciences, where pharmaceutical royalties on approved drugs can generate cash flows for the remaining life of a patent; and consumer and media, where streaming royalties and brand licensing fees have become a more formalized asset class over the past decade.
Natural resource royalties have the longest institutional track record and the most developed secondary market, which makes them the natural starting point for family offices entering the space. A royalty on a producing copper mine, for example, requires no operational involvement from the royalty holder, carries no cost-of-production exposure, and benefits directly from commodity price appreciation without the capital intensity of actually running the mine. The royalty company or fund simply receives its percentage off the top of production revenue. That structure is almost cartoonishly favorable from a capital efficiency standpoint, which is exactly why the entry prices are rarely cheap when buying from established royalty companies.
The life sciences segment is where the most interesting deal flow appears to be emerging for private capital. When a mid-size biotech company needs cash and cannot access public markets at reasonable valuations, selling a royalty on an existing approved drug can be more attractive than a dilutive equity raise or a restrictive debt facility. The fund prices the royalty based on projected drug sales, patent life, and competitive landscape, then holds through the remaining commercial window. The risk is entirely about forecasting commercial adoption rather than credit quality, which is a different analytical skill set – and one that family offices with science-oriented principals or advisors are well positioned to develop.
Consumer brand royalties occupy a smaller but growing corner of this market. A regional food brand or a mid-tier apparel label might license its name and intellectual property in exchange for upfront capital, with the licensor receiving a royalty on all sales bearing the brand. For the fund, the return depends on brand durability rather than interest rate cycles or credit spreads. That makes consumer royalties a genuinely uncorrelated return source, which is valuable in a portfolio where most private credit exposure is still tied, at some level, to the broader debt market.
The structure also allows for creative deal construction that straight debt cannot accommodate. A royalty agreement can include caps – maximum total payments that effectively convert the royalty into a fixed sum once reached – or floors that guarantee minimum payments regardless of revenue performance. Some funds are layering in conversion rights that allow the royalty holder to convert their position into equity if the company reaches certain performance thresholds. That optionality is worth real money and represents a structural feature that institutional lenders in conventional credit markets rarely negotiate.
The Risks That Don’t Always Get Priced In
The main risk in royalty-based lending is revenue forecasting error. Because returns depend on actual commercial performance rather than a contractual payment schedule, a fund that mismodels a drug’s peak sales or overestimates a commodity royalty’s production life can underperform badly even if the underlying company never defaults. This is not a credit risk in the traditional sense – it is a projection risk, and it is harder to hedge. Due diligence in this space requires a level of sector-specific commercial analysis that goes well beyond reading a borrower’s balance sheet.
There is also a liquidity consideration that family offices have to weigh carefully. Royalty fund stakes are illiquid by design, and the secondary market for individual royalty agreements – outside of the publicly traded royalty companies – remains thin. For a family office with a 10- to 20-year capital deployment horizon, that is often acceptable. But any family office that might need to liquidate positions on shorter notice, whether because of generational transitions or changing tax situations, needs to build that constraint into its position sizing from the start. The return profile is attractive precisely because liquidity has been surrendered, and that trade should be made with clear eyes.
